JPRN-UMIN000008110Recruiting未知
Aprepitant, Palonosetron and Dexamethasone Antiemetic Therapy Evaluation trial in germ cell tumor (APDATE) - Antiemetic therapy in germ cell tumor
Department of Urology, Sapporo Medical University School of Medicine0 sites30 target enrollmentStarted: June 5, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Uncontrollable complications 2. Brain metastasis 3. Active convulsive disease 4. Plural effusion or ascites requiring puncture 5. Obstruction of the gastric outlet or ileus 6. Vomiting or severe nausea before the chemotherapy 7. Anaphylaxis against 5-HT3 receptor inhibitors, aprepitant or dexamethasone 8. Disapproval of contraception 9. History og aprepitant or palonostron 10. Participation of other clinical trials of antiemetics
Investigators
Similar Trials
Completed
Phase 2
Study of Aprepitant / Palonosetron / Dexamethasone for nausea and vomiting induced chemotherapy for breast cancer.Breast cancerJPRN-UMIN000004025Saitama Breast Cancer Clinical Study Group(SBCCSG)55
Completed
Phase 2
Palonosetron+Aprepitant+Dexamethasone for highly emetic chemotherapy induced nausea and voimitingJPRN-UMIN000004865iigata Lung Cancer Treatment Group95
Recruiting
Phase 2
Palonosetoron+Aprepitant+Dexamethasone Therapy in patients receiving moderately emetogenic anticancer drugs (EJCG-1001)ung cancerJPRN-UMIN000006498East Japan Chesters Group (EJCG)90
Completed
Phase 2
Palonosetron+Aprepitant+Dexamethasone for moderately emetic chemotherapy induced nausea and voimiting-Phase II studyung cancerJPRN-UMIN000004936iigata Lung Cancer Treatment Group160
Completed
Not Applicable
comparision between Aprepitant and Dexamethasone For Preventing Postoperative Nausea And Vomiting In Breast Cancer PatientsCTRI/2014/12/005333AIIMS160